https://www.selleckchem.com/products/apd334.html Photodynamic therapy (PDT) mostly relies on the generation of singlet oxygen, via the excitation of a photosensitizer, so that target tumor cells can be destroyed. PDT can be applied in the settings of several malignant diseases. In fact, the earliest preclinical applications date back to 1900's. Dougherty reported the treatment of skin tumors by PDT in 1978. Several further studies around 1980 demonstrated the effectiveness of PDT. Thus, the technique has attracted the attention of numerous researchers since then. Hematoporphyrin derivative received the FDA approval as a clinical application of PDT in 1995. We have indeed witnessed a considerable progress in the field over the last century. Given the fact that PDT has a favorable adverse event profile and can enhance anti-tumor immune responses as well as demonstrating minimally invasive characteristics, it is disappointing that PDT is not broadly utilized in the clinical setting for the treatment of malignant and/or non-malignant diseases. Several issues stat aim to overcome the limitations and reveal the full potential of PDT in terms of clinical translation are undoubtedly exciting. A better understanding of novel concepts in the field (e.g. enhanced, two-stage, fractional PDT) will most likely prove to be very useful for pursuing and improving effective PDT strategies.Deep eutectic solvents (DESs) are considered as a green and environmentally benign solvent class for various applications, including delignification of biomass. One of the major challenges in the delignification of biomass by DES is attributed to the limitations in mass transfer. By subjecting wood chips to a low-energy mechanical refining, i.e., the Asplund process, the accessible surface area increases greatly, which in turn improves the mass transfer and increases the reaction rate. In this research, the DES delignification of Asplund fibers made of Norway spruce was studied as a strategy to prod